These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19815482)

  • 21. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer.
    Sharma NK; Li T; Chen DY; Pollack A; Horwitz EM; Buyyounouski MK
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):437-44. PubMed ID: 21050673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
    Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
    Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer.
    Wilder RB; Barme GA; Gilbert RF; Holevas RE; Kobashi LI; Reed RR; Solomon RS; Walter NL; Chittenden L; Mesa AV; Agustin J; Lizarde J; Macedo J; Ravera J; Tokita KM
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):824-30. PubMed ID: 20510195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer.
    Xu N; Rossi PJ; Jani AB
    Am J Clin Oncol; 2011 Feb; 34(1):11-5. PubMed ID: 20101167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: report on dosimetry aspects and acute toxicity in the Indian scenario.
    De S; Kannan V; Deshpande S; Anand V; Ghadi Y
    J Cancer Res Ther; 2010; 6(1):58-64. PubMed ID: 20479549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy.
    Yoon M; Ahn SH; Kim J; Shin DH; Park SY; Lee SB; Shin KH; Cho KH
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1477-85. PubMed ID: 19879701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose escalation in image-guided, intensity-modulated radiotherapy of carcinoma prostate: initial experience in India.
    Swamy K; Sathiya Narayanan VK; Basu S; Maiya V; Achari R; Deshpande S; Bhangle J; Gupta KK; Babu N; Pawar S; Atre A; Balachandra K; Koppiker CB
    J Cancer Res Ther; 2009; 5(4):277-83. PubMed ID: 20160362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost.
    Pinkawa M; Attieh C; Piroth MD; Holy R; Nussen S; Klotz J; Hawickhorst R; Schäfer W; Eble MJ
    Radiother Oncol; 2009 Nov; 93(2):213-9. PubMed ID: 19717197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: impact of previous surgery for benign prostatic hyperplasia.
    Odrazka K; Dolezel M; Vanasek J; Vaculikova M; Zouhar M; Sefrova J; Paluska P; Vosmik M; Kohlova T; Kolarova I; Navratil P; Brodak M; Prosvic P; Hoffmann P
    Int J Urol; 2010 Sep; 17(9):784-90. PubMed ID: 20604816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
    Martinez AA; Gonzalez J; Ye H; Ghilezan M; Shetty S; Kernen K; Gustafson G; Krauss D; Vicini F; Kestin L
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):363-70. PubMed ID: 21195875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.
    Lips I; Dehnad H; Kruger AB; van Moorselaar J; van der Heide U; Battermann J; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):656-61. PubMed ID: 17512127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
    Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
    Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to "the impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy" (Int J Radiat Oncol Biol Phys 2011;79:379-384).
    Oymak E; Onal C
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1603; author reply 1603-4. PubMed ID: 21740997
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer.
    Yuen J; Rodrigues G; Trenka K; Coad T; Yartsev S; D'Souza D; Lock M; Bauman G
    Radiat Oncol; 2008 Jan; 3():1. PubMed ID: 18179695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study.
    Marchand V; Bourdin S; Charbonnel C; Rio E; Munos C; Campion L; Bonnaud-Antignac A; Lisbona A; Mahé MA; Supiot S
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1053-9. PubMed ID: 19880259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.